Monoclonal antibodies against amyloid beta protein and uses thereof

US10323084B2 · kind B2 · utility

Assignees

• Abb Vie Inc. · US
• Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

• Heinz Hillen · Herbrechtingen, DE
• Stefan Barghorn · Mannheim, DE
• Boris Labkovsky · Framingham, US
• Ulrich Ebert · Mannheim, DE
• Andreas Striebinger · Speyer, DE
• Patrick Keller · Darmstadt, DE

Key dates

• Filing date: Jul 27, 2017
• Grant date: Jun 18, 2019
• Expiry date: Jul 27, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2821
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.